Aptamer Group (APTA) Competitors GBX 0.36 -0.01 (-1.92%) As of 08/1/2025 11:23 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsBuy This Stock APTA vs. SAR, OKYO, AREC, AOR, POLB, RLM, NSCI, OPTI, IXI, and OBDShould you be buying Aptamer Group stock or one of its competitors? The main competitors of Aptamer Group include Sareum (SAR), OKYO Pharma (OKYO), Arecor Therapeutics (AREC), AorTech International (AOR), Poolbeg Pharma (POLB), Realm Therapeutics (RLM), NetScientific (NSCI), OptiBiotix Health (OPTI), IXICO (IXI), and Oxford BioDynamics (OBD). These companies are all part of the "biotechnology" industry. Aptamer Group vs. Its Competitors Sareum OKYO Pharma Arecor Therapeutics AorTech International Poolbeg Pharma Realm Therapeutics NetScientific OptiBiotix Health IXICO Oxford BioDynamics Aptamer Group (LON:APTA) and Sareum (LON:SAR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends. Which has more volatility and risk, APTA or SAR? Aptamer Group has a beta of -0.52, indicating that its stock price is 152% less volatile than the S&P 500. Comparatively, Sareum has a beta of -1.08, indicating that its stock price is 208% less volatile than the S&P 500. Is APTA or SAR more profitable? Sareum has a net margin of 0.00% compared to Aptamer Group's net margin of -343.95%. Aptamer Group's return on equity of -205.63% beat Sareum's return on equity.Company Net Margins Return on Equity Return on Assets Aptamer Group-343.95% -205.63% -44.96% Sareum N/A -270.25%-113.80% Does the media favor APTA or SAR? In the previous week, Aptamer Group's average media sentiment score of 0.00 equaled Sareum'saverage media sentiment score. Company Overall Sentiment Aptamer Group Neutral Sareum Neutral Do insiders and institutionals have more ownership in APTA or SAR? 11.7% of Aptamer Group shares are held by institutional investors. 13.2% of Aptamer Group shares are held by insiders. Comparatively, 5.0% of Sareum shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has better valuation & earnings, APTA or SAR? Sareum has lower revenue, but higher earnings than Aptamer Group. Sareum is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAptamer Group£4.12M1.73-£14.17M-£0.71-0.50SareumN/AN/A-£5.28M-£4.22-4.01 SummaryAptamer Group beats Sareum on 8 of the 10 factors compared between the two stocks. Get Aptamer Group News Delivered to You Automatically Sign up to receive the latest news and ratings for APTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APTA vs. The Competition Export to ExcelMetricAptamer GroupBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£7.12M£134.48M£5.49B£3.03BDividend YieldN/A3.74%4.73%5.02%P/E Ratio-0.503.8128.75176.75Price / Sales1.734,246.60372.20264,362.45Price / CashN/A13.1935.4527.97Price / Book1.6839.388.274.53Net Income-£14.17M-£90.99M£3.25B£5.90B7 Day Performance1.99%-1.82%-3.72%12.58%1 Month Performance-1.38%11.23%4.30%6.10%1 Year Performance52.34%189.82%25.87%71.60% Aptamer Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APTAAptamer GroupN/AGBX 0.36-1.9%N/A+27.9%£7.12M£4.12M-0.5037Gap DownSARSareumN/AGBX 18.90+5.0%N/A-43.5%£23.61MN/A-4.483,211OKYOOKYO PharmaN/AN/AN/AN/A£23.24MN/A-140.007Gap DownARECArecor TherapeuticsN/AGBX 55+5.8%N/A-36.3%£20.77M£6.04M-1.9410News CoverageHigh Trading VolumeAORAorTech InternationalN/AN/AN/AN/A£19.99M£539K-33.383POLBPoolbeg PharmaN/AGBX 2.89-6.8%N/A-77.1%£14.85MN/A0.0012High Trading VolumeRLMRealm TherapeuticsN/AN/AN/AN/A£13.41M£501.92K-0.66N/ANSCINetScientificN/AN/AN/AN/A£12.81M£1.45M-486.3626OPTIOptiBiotix HealthN/AGBX 11.50+2.2%N/A-54.4%£11.26M£590.01K-3.641IXIIXICON/AGBX 11.80+12.4%N/A+73.5%£10.94M£11.50M-3.0689Gap UpHigh Trading VolumeOBDOxford BioDynamicsN/AGBX 0.49-5.8%N/A-92.3%£9.14M£5.75M-0.0945 Related Companies and Tools Related Companies Sareum Alternatives OKYO Pharma Alternatives Arecor Therapeutics Alternatives AorTech International Alternatives Poolbeg Pharma Alternatives Realm Therapeutics Alternatives NetScientific Alternatives OptiBiotix Health Alternatives IXICO Alternatives Oxford BioDynamics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:APTA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptamer Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptamer Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APTA Stock Alerts